S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
Log in

NASDAQ:ATRAAtara Biotherapeutics Price Target & Analyst Ratings

$12.65
+0.10 (+0.80 %)
(As of 08/7/2020 02:14 PM ET)
Add
Compare
Today's Range
$12.35
Now: $12.65
$13.00
50-Day Range
$10.54
MA: $13.42
$15.50
52-Week Range
$4.52
Now: $12.65
$19.36
Volume23,234 shs
Average Volume744,596 shs
Market Capitalization$745.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23

Analyst Ratings

Atara Biotherapeutics (NASDAQ:ATRA) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Atara Biotherapeutics in the last 12 months. Their average twelve-month price target is $28.11, suggesting that the stock has a possible upside of 122.22%. The high price target for ATRA is $70.00 and the low price target for ATRA is $9.00. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.642.642.55
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.11$23.75$29.88$29.88
Price Target Upside: 122.22% upside75.67% upside264.77% upside103.65% upside

Atara Biotherapeutics (NASDAQ:ATRA) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Atara Biotherapeutics (NASDAQ:ATRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/6/2020Stifel NicolausLower Price TargetBuy$30.00 ➝ $28.00Low
8/6/2020HC WainwrightBoost Price TargetBuy$25.00 ➝ $26.00High
7/17/2020Canaccord GenuityReiterated RatingBuy$70.00Medium
6/30/2020Evercore ISIInitiated CoverageOutperformMedium
5/26/2020MizuhoInitiated CoverageBuy$38.00High
5/12/2020JPMorgan Chase & Co.Boost Price TargetNeutral$22.00 ➝ $23.00High
4/23/2020CitigroupUpgradeNeutral ➝ Buy$14.00High
12/10/2019CowenReiterated RatingBuyMedium
9/27/2019Goldman Sachs GroupDowngradeNeutral ➝ Sell$14.00 ➝ $9.00Medium
9/16/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $15.00Medium
9/13/2019Roth CapitalInitiated CoverageBuy$30.00High
5/29/2019WedbushReiterated RatingOutperformHigh
5/16/2019William BlairReiterated RatingBuyLow
3/15/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
2/28/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
(Data available from 8/7/2018 forward)
This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.